Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting - Summary of Net Revenue, Cost of Sales, Depreciation and Amortization, Operating Profit, Interest Expense, Income Tax Expense and Assets by Segment (Detail)

v3.21.1
Segment Reporting - Summary of Net Revenue, Cost of Sales, Depreciation and Amortization, Operating Profit, Interest Expense, Income Tax Expense and Assets by Segment (Detail) - USD ($)
 3 Months Ended
Feb. 28, 2021
Feb. 29, 2020
Nov. 30, 2020
Segment Reporting Information [Line Items]      
Revenue $ 6,860,617 $ 7,620,774  
Cost of sales 2,012,197 2,503,144  
Depreciation and amortization 21,263 44,221  
Total operating income 1,235,261 1,249,070  
Total interest expense 280,219 365,299  
Total assets 105,264,461   $ 46,200,094
Operating Segments [Member]      
Segment Reporting Information [Line Items]      
Depreciation and amortization 21,263 44,221  
Umbilical Cord Blood and Cord Tissue Stem Cell Service [Member]      
Segment Reporting Information [Line Items]      
Revenue 6,738,631 7,406,288  
Cost of sales 1,640,015 2,055,075  
Total operating income 1,492,353 1,489,548  
Total interest expense 280,219 365,299  
Total assets 93,405,068   34,215,780
Umbilical Cord Blood and Cord Tissue Stem Cell Service [Member] | Operating Segments [Member]      
Segment Reporting Information [Line Items]      
Depreciation and amortization 14,368 37,327  
PrepaCyte CB [Member]      
Segment Reporting Information [Line Items]      
Revenue 38,000 60,407  
Cost of sales 34,880 41,117  
Total operating income (3,777) 12,396  
Total assets 235,248   302,683
PrepaCyte CB [Member] | Operating Segments [Member]      
Segment Reporting Information [Line Items]      
Depreciation and amortization 6,895 6,894  
Public Cord Blood Banking [Member]      
Segment Reporting Information [Line Items]      
Revenue 83,986 154,079  
Cost of sales 337,302 406,952  
Total operating income (253,315) $ (252,874)  
Total assets $ 11,624,145   $ 11,681,631